They found degradation of Bcl-XL resulted in apoptosis of Tregs and activation of CD8+ T-cells, noting that small-molecule PROTACs for Bcl-XL can be promising adjuvant agents in tumor immunotherapy [68,150]. This evidence concerns the gene CD8A and neoplasm.